- Active not recruitingPHASE3
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This study is looking at different ways of giving a medicine called donanemab for early Alzheimer's disease. Researchers want to see how different doses affect side effects and which patients might be more likely to experience them. It's for adults aged 60-85.
For: Alzheimer's Disease · Dementia · Brain DiseasesUnited States · United Kingdom - Active not recruitingPHASE3
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This study is looking at a new medicine called donanemab for people in the early stages of Alzheimer's disease. Researchers want to find out if it's safe and effective at treating the condition. Some people will get the medicine, and others a dummy treatment.
For: Alzheimer DiseaseUnited States · Australia · Canada - Active not recruitingPHASE3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
This study is testing a new medication called donanemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow memory and thinking problems. It's a key step in understanding potential new treatments for this condition.
For: Alzheimer Disease · Dementia · Brain DiseasesArgentina · Australia · China - Ongoing, recruitingTherapeutic confirmatory (Phase III)
I5T-MC-AACQ: Investigating the Effect of Different Donanemab Dosing Regimens on ARIA-E and Amyloid Lowering in Adults with Early Symptomatic Alzheimer’s Disease
This study is looking at how different amounts of the drug donanemab affect swelling in the brain (ARIA-E) and reduce amyloid — a protein linked to Alzheimer's disease. It's for adults in the early stages of Alzheimer's.
For: Neurocognitive Disorders · Central Nervous System Diseases · Neurodegenerative DiseasesItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
I5T-MC-AACI: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
This study, called I5T-MC-AACI, is looking at a new medicine called Donanemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe, how well people tolerate it, and if it helps with symptoms. It's a Phase II study, which means it's still in early testing.
For: Alzheimer DiseaseNetherlands · Czechia · Poland